Eisai, Arena to launch obesity drug next month

05/9/2013 | PharmaTimes (U.K.)

Eisai and Arena Pharmaceuticals plan to launch their antiobesity drug Belviq, or lorcaserin, in the U.S. next month following the drug's classification as a Schedule IV controlled substance. Belviq was approved by the FDA last year for chronic weight management in obese adults who suffer from at least one weight-related condition. The launch triggers the payment of a $65 million milestone fee from Eisai to Arena.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care